



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at the Leerink Partners 5<sup>th</sup> Annual Global Healthcare Conference**

*Heidelberg, Germany, February 4, 2016* - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Leerink Partners 5<sup>th</sup> Annual Global Healthcare Conference on Thursday, February 11, 2016 at 11:10 a.m. (ET) in New York City.

To access a simultaneous webcast of Dr. Hoess' presentation online, log on to <http://wsw.com/webcast/leerink26/afmd> or go to the "Events" section on the "Media" page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at <http://www.affimed.com/events.php>.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit [www.affimed.com](http://www.affimed.com).

**IR Contact:**

Caroline Stewart, Head of IR

Phone: +1 347394 6793

E-Mail: [IR@affimed.com](mailto:IR@affimed.com) or [c.stewart@affimed.com](mailto:c.stewart@affimed.com)

**Media Contact:**

Anca Alexandru, Head of Communications

Phone: +49 6221 64793341

E-Mail: [a.alexandru@affimed.com](mailto:a.alexandru@affimed.com)